AAM Applauds 232 Investigation Executive Order on Pharmaceuticals
Thanks the Administration for working with AAM and industry WASHINGTON (April 2, 2026) — The Association for Accessible Medicines today applauded the proclamation signed by
Thanks the Administration for working with AAM and industry WASHINGTON (April 2, 2026) — The Association for Accessible Medicines today applauded the proclamation signed by
FDA draft guidance removes redundant PK testing requirements where scientifically rigorous data already exists WASHINGTON (March 10, 2026) — The Association for Accessible Medicines and
ACCESS! 2026 Day 2 Recap: New Leadership, Hard Data, and a View from the Top After a memorable first evening capped by a Candlelight by
Bob Hoffman, Chief Commercial Officer of U.S. Generics at Lupin Pharmaceuticals, was introduced as the incoming AAM Board Chair at ACCESS! 2026 in Miami, succeeding
ACCESS! 2026 Day 1 Recap: Weathering Every Storm to Protect Patient Access Leaders and luminaries in the generic and biosimilars community descended on Miami for
2025 Savings Report 2025 U.S. Generic & Biosimilar Medicines Savings Report Learn More From Axios AAM’s annual savings report, in partnership with the IQVIA Institute,
Outlines four key policy areas Congress can act on now to protect generic and biosimilar medicines and provide access and savings for patients WASHINGTON (February
Applauds Q1/Q2 passage; Calls for additional PBM reform WASHINGTON (February 3, 2026) — The Association for Accessible Medicines today applauded passage of Q1/Q2 legislation as
WASHINGTON (January 29, 2026) — The Board of Directors of the Association for Accessible Medicines has elected Bob Hoffman as Chair. Hoffman, Chief Commercial Officer
Call for passage of Biosimilar Red Tape Elimination Act WASHINGTON (January 22, 2026) — The Biosimilars Council and the Association for Accessible Medicines sent a
Calls for support, continuity, and consistency at the agency WASHINGTON (December 8, 2025) — The Association for Accessible Medicines, the leading trade association for generic
Allows quicker market entry of generic and biosimilar competition, reducing prices across the healthcare landscape, protecting patient access to affordable medicines WASHINGTON (December 8, 2025)
